Vitamin D in Corona Virus Disease 2019 (COVID-19) Related Multisystem Inflammatory Syndrome in Children (MIS-C)
Front Immunol. 2021 Mar 8;12:648546. doi: 10.3389/fimmu.2021.648546
Gavriela Feketea 1 2, Vasiliki Vlacha 3, Ioana Corina Bocsan 4, Emilia Vassilopoulou 5, Luminita Aurelia Stanciu 6, Mihnea Zdrenghea 1 7
This list is automatically updated
- COVID children with multisystem inflammatory syndrome have less than 10 ng of vitamin D – March 2022
- 8 of 10 pediatric COVID-19 infections were Vitamin D deficient (49 patients) – May 2021
- Hospitalized children with COVID-19 and inflammation had lower vitamin D – March 2021
- Vitamin D might reduce Multisystem Inflammatory Syndrome in children – March 2021
Also known as Paediatric Inflammatory Multisystem Syndrome
Is apparently similar to Kawasaki disease
Multisystem Inflammatory Syndrome in children (MIS-C) is a rare but devastating complication of coronavirus disease 19 (COVID-19). The development of prognostic biomarkers and more importantly the implementation of new treatment modalities would have a significant impact in clinical practice regarding the outcome of MIS-C. Vitamin D could be a potential candidate. In this mini review we analyze the immunomodulatory role of vitamin D in viral infections and specifically in COVID-19. We also examine the current literature regarding the association of vitamin D with MIS-C and Kawasaki disease. The vitamin D was evaluated not only as a biomarker but also as a nutritional supplement.
We concluded that vitamin D levels could be valuable in predicting severe forms of MIS-C and correction of abnormal levels in severe MIS-C may influences its evolution. 25-hydroxyvitamin D3 [25(OH)D3] supplementation raising serum [25(OH)D] concentrations potentially have a favorable effect in reducing the severity of MIS-C in certain circumstances. Further studies are needed to confirm these results.